Bridgebio Oncology Therapeutics, Inc. engages in developing bioavailable small molecule inhibitors. It focuses on advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. The company was founded on August 1, 2016 and is headquartered in South San Francisco, CA.
Fundamentals
Mkt Cap
$228.5M
Volume
-
52W High
$14.87
52W Low
$2.79
PE Ratio
0.00
Avg. Volume
726,370.73
EPS (Annual)
-$4.30
P/B
0.71
Rev/Employee
$0.00
Earnings
Nov 11
52
Neutral Sentiment
How do you feel about BBOT?
PhishTourFunds
$BBOT đź‘€
That volume candle was almost 1M shares traded in a ten minute window. Average daily volume is just over 700,000